Overview

Treatment of High-Risk Cerebral Primitive Neuroectodermal Tumors in Children Aged Over 5 Years

Status:
Completed
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
Primary objective : To increase the 3 year progression-free survival from 40% to 60%. Patients included : metastatic, cerebral primitive neuroectodermal tumors in children aged over 5 years.
Phase:
Phase 2
Details
Lead Sponsor:
Gustave Roussy, Cancer Campus, Grand Paris
Treatments:
Carboplatin
Etoposide
Etoposide phosphate
Thiotepa